Is CRISPR Therapeutics Stock a Buy Now?

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

CRISPR Therapeutics Balances CASGEVY Momentum With Early Pipeline Uncertainty

CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial momentum for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company is preparing a regulatory ...
Business Insider

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...

Here is Why CRISPR Therapeutics (CRSP) Appears so Good

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

How CRISPR Works: Unpacking the Science of Cas9 and Gene Modification

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.